Fig 7. INI-4001-adjuvanted vaccine elicits durable antibody response with long-lasting protection.

(A-B) Mice vaccinated twice 4 weeks apart. Serum collected monthly for ~9 months post-boost and analyzed by whole-virus ELISA for IgG titer or reciprocal FRNT50 assay for neutralizing titers. (A,B) Data are log transformed and reported as means ± SEM. Statistical significance was calculated by repeated measure two-way ANOVA and Šídák’s multiple comparisons test to compare TLR agonist treatments to alum-treated group after log transformation: * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001. Dotted line represents least dilute sera tested (1:50). (C) Neutralization activity of sera 36 weeks post-boost as measured by percent of foci per well of serum-treated virus relative to untreated control. Data represent treatment-group mean percentages ± SEM. Lines represent non-linear regression curves. (D) Mice infected ip at 9 months post-boost with 10⁴ FFU POWV-LB. Survival monitored for 21 days. Statistical significance determined by log rank test with Bonferroni correction to compare adjuvant groups to alum treatment. All data represent single experiment. n=4 for alum; n=5/group for all other groups.